OpenURL Connection Search

Select item for more details and to access through your institution.

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Published in:
2021
By:
- Graeser, Monika;
- Schrading, Simone;
- Gluz, Oleg;
- Strobel, Kevin;
- Herzog, Christopher;
- Umutlu, Lale;
- Frydrychowicz, Alex;
- Rjosk-Dendorfer, Dorothea;
- Würstlein, Rachel;
- Culemann, Ralph;
- Eulenburg, Christine;
- Adams, Jascha;
- Nitzsche, Henrik;
- Prange, Anna;
- Kümmel, Sherko;
- Grischke, Eva-Maria;
- Forstbauer, Helmut;
- Braun, Michael;
- Potenberg, Jochem;
- von Schumann, Raquel
Publication type:
journal article
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Published in:
Cancers, 2021, v. 13, n. 19, p. 4884, doi. 10.3390/cancers13194884
By:
- Harbeck, Nadia;
- von Schumann, Raquel;
- Kates, Ronald Ernest;
- Braun, Michael;
- Kuemmel, Sherko;
- Schumacher, Claudia;
- Potenberg, Jochem;
- Malter, Wolfram;
- Augustin, Doris;
- Aktas, Bahriye;
- Forstbauer, Helmut;
- Tio, Joke;
- Grischke, Eva-Maria;
- Biehl, Claudia;
- Liedtke, Cornelia;
- De Haas, Sanne Lysbet;
- Deurloo, Regula;
- Wuerstlein, Rachel;
- Kreipe, Hans Heinrich;
- Gluz, Oleg
Publication type:
Article
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Published in:
Breast Care, 2021, v. 16, n. 1, p. 50, doi. 10.1159/000506622
By:
- Wuerstlein, Rachel;
- Harbeck, Nadia;
- Grischke, Eva-Maria;
- Forstmeyer, Dirk;
- von Schumann, Raquel;
- Krabisch, Petra;
- Lüdtke-Heckenkamp, Kerstin;
- Stefek, Andrea;
- Stoetzer, Oliver;
- Grafe, Andrea;
- Kaltenecker, Gabriele;
- Forstbauer, Helmut;
- Augustin, Doris;
- Schrader, Iris;
- Tio, Joke;
- Nitz, Ulrike;
- Gluz, Oleg;
- Kates, Ronald E.;
- Graeser, Monika Karla
Publication type:
Article
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Published in:
International Journal of Cancer, 2021, v. 148, n. 10, p. 2614, doi. 10.1002/ijc.33495
By:
- Graeser, Monika;
- Schrading, Simone;
- Gluz, Oleg;
- Strobel, Kevin;
- Würstlein, Rachel;
- Kümmel, Sherko;
- Schumacher, Claudia;
- Grischke, Eva-Maria;
- Forstbauer, Helmut;
- Braun, Michael;
- Christgen, Matthias;
- Adams, Jascha;
- Nitzsche, Henrik;
- Just, Marianne;
- Fischer, Hans Holger;
- Aktas, Bahriye;
- Potenberg, Jochem;
- Schumann, Raquel von;
- Kolberg-Liedtke, Cornelia;
- Harbeck, Nadia
Publication type:
Article
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Published in:
2018
By:
- Gluz, Oleg;
- Nitz, Ulrike;
- Liedtke, Cornelia;
- Christgen, Matthias;
- Grischke, Eva-Maria;
- Forstbauer, Helmut;
- Braun, Michael;
- Warm, Mathias;
- Hackmann, John;
- Uleer, Christoph;
- Aktas, Bahriye;
- Schumacher, Claudia;
- Bangemann, Nikola;
- Lindner, Christoph;
- Kuemmel, Sherko;
- Clemens, Michael;
- Potenberg, Jochem;
- Staib, Peter;
- Kohls, Andreas;
- von Schumann, Raquel
Publication type:
journal article

Found: 5

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.